Heparin - Messias or Verschlimmbesserung?

Area of Science:

• Internal Medicine
• Hematology
• Infectious Diseases

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a high risk of thrombosis.
• Heparin anticoagulation was widely used during the coronavirus disease 2019 (COVID-19) pandemic to mitigate thrombotic risks.

Purpose of the Study:

• To explore potential mechanisms behind heparin's apparent failure to prevent thrombotic events in COVID-19 patients.
• To review the role of anti-Xa assays and global hemostatic tests in managing heparin therapy for COVID-19.
• To discuss the controversy surrounding heparin dosing in COVID-19 and its mechanistic underpinnings.

Main Methods:

• Literature review focusing on heparin efficacy and failure in COVID-19.
• Analysis of proposed pathophysiological mechanisms for anticoagulant resistance.
• Examination of diagnostic assays (anti-Xa, global hemostatic tests) in the context of COVID-19-associated coagulopathy.

Main Results:

• Reports indicate instances where heparin anticoagulation did not prevent thrombotic events in hospitalized COVID-19 patients.
• Potential mechanisms for heparin resistance in COVID-19 include inflammatory mediators and altered protein binding.
• The utility and interpretation of anti-Xa assays and global hemostatic tests in this specific patient population are under investigation.

Conclusions:

• Heparin failure in COVID-19 is a complex issue potentially driven by disease-specific pathophysiology.
• Understanding these mechanisms is crucial for optimizing anticoagulant strategies in COVID-19 and future viral pandemics.
• Further research is needed to guide appropriate heparin dosing and selection of anticoagulants in severe infections.